PMID- 24100249
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20181202
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 38
DP  - 2014 Sep
TI  - Gene therapy for epilepsy.
PG  - 125-30
LID - S1525-5050(13)00479-4 [pii]
LID - 10.1016/j.yebeh.2013.09.013 [doi]
AB  - Gene therapy may represent an effective alternative to standard pharmacological 
      approaches for certain forms of epilepsy. Currently, the best candidates for this 
      therapeutic approach appear to be epilepsies characterized by a focal lesion. 
      Gene therapy has been attempted to produce antiepileptogenic (prevention of 
      development of epilepsy in subject at risk after having received an epileptogenic 
      insult), antiseizure (reduction of frequency and/or severity of seizures), and 
      disease-modifying (alteration of the natural history of the disease) effects. An 
      example of gene therapy aimed at producing antiepileptogenic effects is a 
      combination therapy based on the supplementation of the neurotrophic factors 
      brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 2 (FGF-2). 
      Antiseizure effects have been obtained by increasing the strength of inhibitory 
      signals (by supplementing specific GABAA receptor subunits or inhibitory 
      neuropeptides like galanin or neuropeptide Y) or by reducing the strength of 
      excitatory signals (by knocking down NMDA receptor subunits). This review 
      summarizes the results obtained to date using gene therapy in epilepsy models and 
      discusses the challenges and the opportunities that this approach can offer for 
      the treatment of human epilepsies.
CI  - (c) 2013.
FAU - Simonato, Michele
AU  - Simonato M
AD  - Department of Medical Sciences, Section of Pharmacology and Neuroscience Center, 
      University of Ferrara, Italy; National Institute of Neuroscience, University of 
      Ferrara, Italy; Laboratory for Technologies of Advanced Therapies (LTTA), 
      University of Ferrara, Italy. Electronic address: michele.simonato@unife.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131005
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuropeptide Y)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 88813-36-9 (Galanin)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/genetics/*therapeutic use
MH  - Epilepsy/*therapy
MH  - Fibroblast Growth Factor 2/genetics/*therapeutic use
MH  - Galanin/genetics/*therapeutic use
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Neuropeptide Y/*therapeutic use
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Epileptogenesis
OT  - Galanin
OT  - Neuropeptide Y
OT  - Seizures
OT  - Viral vectors
EDAT- 2013/10/09 06:00
MHDA- 2015/09/04 06:00
CRDT- 2013/10/09 06:00
PHST- 2013/08/30 00:00 [received]
PHST- 2013/09/06 00:00 [revised]
PHST- 2013/09/06 00:00 [accepted]
PHST- 2013/10/09 06:00 [entrez]
PHST- 2013/10/09 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
AID - S1525-5050(13)00479-4 [pii]
AID - 10.1016/j.yebeh.2013.09.013 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2014 Sep;38:125-30. doi: 10.1016/j.yebeh.2013.09.013. Epub 2013 
      Oct 5.